📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency. (2016)

First Author: Pytel K

Attributed to: Development of a novel, potent, safe, long-lasting lentivirus-based gene therapy for cystic fibrosis funded by MRC

Abstract

No abstract provided

Bibliographic Information

Publication URI: http://online.liebertpub.com/doi/pdfplus/10.1089/hum.2016.29027.abstracts

Type: Conference/Paper/Proceeding/Abstract

Volume: 27

Issue: 7